These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1774443)

  • 1. Efficacy and tolerability of a long-acting intramuscularly injectable depot preparation of bromocriptine: the results of a double blind study.
    Schulz A; Lancranjan I; Schürmeyer T; Schuppert F; Hesch RD; von zur Mühlen A; Brabant G
    J Endocrinol Invest; 1991 Jun; 14(6):469-74. PubMed ID: 1774443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
    Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.
    Bolanowski M; Milewicz A; Bohdanowicz-Pawlak A; Bednarek-Tupikowska G; Jedrzejak JA; Lancranjan I
    Endokrynol Pol; 1993; 44(4):467-76. PubMed ID: 8055815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C; Moro M; Masala A; Toja P; Alagna S; Brunani A; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI; Bennet AP; James-Deidier A; Tremollieres F; Saint-Martin F; Dumoulin S; Valat-Coustols M; de Glisezinski I; Tremoulet M; Manelfe C; Louvet JP
    J Endocrinol Invest; 1996; 19(7):472-9. PubMed ID: 8884542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
    J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
    Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
    J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
    Pagani MD; Tengattini F; Montini M; Pagani G; Pedroncelli A; Gianola D; Gherardi F; Mazzocchi N; Cortesi L; Lancranjan I
    Clin Endocrinol (Oxf); 1992 Apr; 36(4):369-74. PubMed ID: 1424170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
    Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
    Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemia.
    Ciccarelli E; Grottoli S; Miola C; Avataneo T; Lancranjan I; Camanni F
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):193-8. PubMed ID: 8137517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
    Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
    J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
    Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
    Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.